References
- StonebrakerJSBolton-MaggsPHSoucieJMWalkerIBrookerMA study of variations in the reported haemophilia A prevalence around the worldHaemophilia201016203219845775
- RothDATawaNEJrO’BrienJMTrecoDASeldenRFFactor VIII Transkaryotic Therapy Study GroupNonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia AN Engl J Med20013441735174211396439
- SrivastavaABrewerAKMauser-BunschotenEPGuidelines for the management of hemophiliaHaemophilia201319e1e4722776238
- KavakliKYangRRusenLProphylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)J Thromb Haemost20151336036925546368
- ADVATE®(Antihemophilic Factor [Recombinant]) [package insert], 52011Ontario, CanadaBaxter Healthcare Corporation
- U.S. Food and Drug AdministrationOctober 15, 2013 Approval Letter-Novoeight http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm371095.htmAccessed on May 5, 2016
- SignorovitchJEWuEQYuAPComparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanerceptPharmacoeconomics20102893594520831302
- SignorovitchJESikiricaVErderMHMatching-adjusted indirect comparisons: a new tool for timely comparative effectiveness researchValue Health20121594094722999145
- ErderMHXieJSignorovitchJECost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparisonAppl Health Econ Health Policy20121038139523113551
- Scottish Medicines ConsortiumBristol-Myers Squibb. Daclatasvir 30mg and 60mg film-coated tablets (Daklinza®) SMC No. (1002/14)10102014http://www.scottishmedicines.org.uk/files/advice/daclatasvir_Daklinza_FINAL_Oct_2014_Updated_30.10.14_for_website.pdfAccessed on May 5, 2016
- Australian Government Department of Health - The pharmaceutical benefits schemeEVEROLIMUS, tablets, 5 mg and 10 mg, Afinitor®Novartis Pharmaceuticals Australia Pty Ltd http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2014-03/everolimus-rccAccessed on May 5, 2016
- MoherDLiberatiATetzlaffJAltmanDGGroupPPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementBMJ2009339b253519622551
- Haute Autorité de SantéIndirect Comparisons Methods and ValidityCedex, FranceHAS2009
- BayerTrial to evaluate the efficacy and safety of a new full length Recombinant Human FVIII for hemophilia A (Leopold I) Available from: https://clinicaltrials.gov/ct2/show/NCT01029340. NLM Identifier: NCT01029340Accessed April 13, 2016
- BayerA trial to compare prophylaxis therapy to on-demand therapy with a new full length recombinant FVIII in patients with severe hemophilia A (Leopold II) Available from: https://clinicaltrials.gov/ct2/show/results/NCT01233258. NLM Identifier: NCT01233258Accessed April 13, 2016
- TarantinoMDCollinsPWHayCRClinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia AHaemophilia20041042843715357767
- ValentinoLAMamonovVHellmannAA randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A managementJ Thromb Haemost20121035936722212248
- LentzSRMisgavMOzeloMResults from a large multinational clinical trial (guardian1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacyHaemophilia20131969169723647704
- HigginsJPTGreenSCochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]The Cochrane Collaboration2011 Available from http://handbook.cochrane.org/Accessed on May 5, 2016
- SignorovitchJSwallowEKantorEEverolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparisonExp Hematol Oncol201323224314093